• Home
  • NEW DAY MEDICINE
  • 2 (64) 2024
  • 35 -2 (64) 2024 - Nabieva D.A., Makhamatkhodzhayeva H.B. - ANALYSIS OF DISEASE ACTIVITY INDICES IN PATIENTS WITH ANKYLOSING SPONDYLITIS

35 -2 (64) 2024 - Nabieva D.A., Makhamatkhodzhayeva H.B. - ANALYSIS OF DISEASE ACTIVITY INDICES IN PATIENTS WITH ANKYLOSING SPONDYLITIS

ANALYSIS OF DISEASE ACTIVITY INDICES IN PATIENTS WITH ANKYLOSING SPONDYLITIS

Nabieva D.A. Tashkent Medical Academy

Makhamatkhodzhayeva H.B. Tashkent Medical Academy

Umarova G.K. AKFA Medline, Tashkent sh. Almazarsky district

Resume

The study included 90 patients with ankylosing spondylitis (AS) who received inpatient and outpatient treatment, as well as 20 healthy people who were diagnosed with spondylitis in accordance with the modified New York criteria of 1984 and/or classified criteria developed by ASAS specialists for axial spondylitis in 2009. ASA activity was assessed on the basis of the VAS, BASDAI, ASDAS indices, as well as indicators of CRP and ESR. Evening spinal pain according to VAS data was 6 points, an average of 4.95 according to BASDAI, 3.25 according to ASDAS (CRP), 3.1 according to ASDAS (ESR), CRP, an average of 9 mg/l, ESR on average 19.5 mm/hour.

Keywords: Ankylosing spondylitis, activity levels, correlation analysis

First page

235

Last page

239

For citation: Nabieva D.A., Makhamatkhodzhayeva H.B., Umarova G.K. ANALYSIS OF DISEASE ACTIVITY INDICES IN PATIENTS WITH ANKYLOSING SPONDYLITIS//New Day in Medicine 2(64)2024 235-239 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Ozgocmen S, Khan MA. Current concept of spondyloarthritis: special emphasis on early referral and diagnosis. // Curr Rheumatol Rep 2022;14:409-14.
  2. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. // Trends Immunol 2016;27:17-23.
  3. Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. // Ann Rheum Dis 2018;67:1451-4.
  4. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. // Joint Bone Spine 2017;74:249-53.
  5. Chen W-S, Chang Y-S, Lin K-C, Lai C-C, Wang S-H, Hsiao K-H et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. // J Chin Med Assoc 2022;75:303-8.
  6. Colbert RA, Deodhar AA, Fox D, Gravallese EM, Khan MA, McGonagle D et al. Entheses and bones in spondyloarthritis: 2018 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). // J Rheumatol 2019;36:1527-31.
  7. Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. // Rheumatol Int 2019;29:1343-7.
  8. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. // Clin Rheumatol 2021;30:269-73.
  9. Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. // Rheumatol Int 2015;25:280-4.
  10. Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. // Curr Opin Rheumatol 2018;20:392-7.

    file

    download